Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nimacimab - Bird Rock Bio

Next Previous
Drug Profile

Nimacimab - Bird Rock Bio

Alternative Names: JNJ 2463; Namacizumab; RYI-018

Latest Information Update: 05 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bird Rock Bio
  • Developer Beacon Biosignals; Bird Rock Bio; Skye Bioscience
  • Class Anti-inflammatories; Antifibrotics; Gastrokinetics; Hepatoprotectants; Monoclonal antibodies; Obesity therapies; Urologics
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity
  • No development reported Diabetic nephropathies; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Discontinued Diabetic gastroparesis

Most Recent Events

  • 02 Feb 2026 Efficacy and adverse event data from a phase II trials in Obesity released by Skye Bioscience
  • 12 Jan 2026 Skye Biosciences anticipates completion of Type C meeting in first quarter of 2026
  • 12 Jan 2026 Efficacy and adverse event data from the phase II CBeyond trial in Obesity released by Skye Bioscience

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top